ArticleMucosal immunology2019
IL-22-binding protein exacerbates influenza, bacterial super-infection.
Article in Mucosal immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 46 citations in OpenAlex.
- Therapeutic potential of recombinant IL-22BP in psoriasis: suppression of IL-22/STAT3 signaling in mice.AMB Express · 2025Article
- Post-viral lung diseases: the microbiota as a key player.ERJ open research · 2025Review
- The progress of organ protection mechanisms in sepsis.Frontiers in immunology · 2025Review
- I don't know about you, but I'm feeling IL-22.Cytokine & growth factor reviews · 2024Review
- The role of IL-22 in cancer.Medical oncology (Northwood, London, England) · 2024Review
- IL-22 in Atopic Dermatitis.Cells · 2024Review
- IL-22 Binding Protein Controls IL-22-Driven Bleomycin-Induced Lung Injury.The American journal of pathology · 2024Article
- Bronchoscopy and molecular diagnostic techniques to identify superimposed infections in COVID-19-associated ARDS: a case series from Ecuador during the second wave.Frontiers in medicine · 2024Article
- Article
- COVID-19 and influenza infections mediate distinct pulmonary cellular and transcriptomic changes.Communications biology · 2023Article
- Epithelial plasticity and innate immune activation promote lung tissue remodeling following respiratory viral infection.Nature communications · 2023Article
- Review
- Selenium Nanoparticles Control H1N1 Virus by Inhibiting Inflammatory Response and Cell Apoptosis.Molecules (Basel, Switzerland) · 2023Article
- Current Knowledge of Th22 Cell and IL-22 Functions in Infectious Diseases.Pathogens (Basel, Switzerland) · 2023Review
- Disease tolerance: a protective mechanism of lung infections.Frontiers in cellular and infection microbiology · 2023Review
- The influenza-injured lung microenvironment promotes MRSA virulence, contributing to severe secondary bacterial pneumonia.Cell reports · 2022Article
- Interleukin-22 attenuates allergic airway inflammation in ovalbumin-induced asthma mouse model.BMC pulmonary medicine · 2021Article
- Review
- Review
- Airway tight junctions as targets of viral infections.Tissue barriers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Secondary bacterial pneumonia is a significant complication of severe influenza infection and Staphylococcus aureus and Streptococcus pneumoniae are the primary pathogens of interest. IL-22 promotes S. aureus and S. pneumoniae host defense in the lung through epithelial integrity and induction of antimicrobial peptides and is inhibited by the soluble decoy receptor IL-22-binding protein (IL-22BP). Little is known about the effect of the IL-22/IL-22BP regulatory pathway on lung infection, and it has not been studied in the setting of super-infection. We exposed wild-type and IL-22BP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.